Rhabdomyolysis and COVID-19 Infection: Is It Due to Statin Use or Anti-TIF1-y Antibodies?

Authors

  • Emmanuel Mantilla John Peter Smith Health Network
  • Dr. Mamatha Pasnoor
  • Dr. Mazen M. Dimachkie

DOI:

https://doi.org/10.17161/rrnmf.v1i3.13719

Keywords:

COVID-19, SARS-CoV-2, rhabdomyolysis, myositis, inflammatory myopathy, anti-TIF1-y antibody

Abstract

Coronavirus disease 2019 (COVID-19), now a global pandemic, has infected millions of people and caused hundreds of thousands of deaths.  Neurological presentation of the novel coronavirus includes headaches, seizures, myalgias, hyposmia, ageusia, etc. Guillain-Barre Syndrome (GBS) and its variant, Miller Fisher Syndrome, have been reported in COVID-19 patients presenting with lower limb weakness, paresthesia, facial diplegia, and ataxia. Most recently, large vessel occlusion strokes were seen in infected younger patients without vascular risk factors. We present a novel case of rhabdomyolysis associated with COVID-19 infection in a patient on atorvastatin, in whom we detected positive anti-transcriptional intermediary factor 1 gamma antibodies (anti-TIF1-y Ab). Bilateral upper and lower extremity weakness improved with aggressive fluid administration and intravenous immunoglobulin (IVIg) at 0.4mg/kg for a total of 5 days. Interrupting a strong cytokine response with IVIg early on during the disease may have led to rapid improvement.

Downloads

Download data is not yet available.

References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020;382(8):727-733. doi:10.1056/nejmoa2001017
2. Bersano A, Pantoni L. On being a neurologist in Italy at the time of the COVID-19 outbreak. Neurology. 2020. doi:10.1212/wnl.0000000000009508
3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061. doi:10.1001/jama.2020.1585
4. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28. PMID: 32109013 doi:10.1101/2020.02.06.20020974
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. doi:10.1016/s0140-6736(20)30183-5
6. Chen N, Zhou M, Dong X, et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019-Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. SSRN Electronic Journal. 2020. doi:10.2139/ssrn.3523861
7. Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. New England Journal of Medicine. 2020. doi:10.1056/nejmc2009191
8. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020. doi:10.1212/wnl.0000000000009619
9. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. New England Journal of Medicine. 2020. doi:10.1056/nejmc2009787
10. Beydon M, Chevalier K, Tabaa OA, et al. Myositis as a manifestation of SARS-CoV-2. Annals of the Rheumatic Diseases. 2020. doi:10.1136/annrheumdis-2020-217573
11. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections. 2020;9(1):727-732. doi:10.1080/22221751.2020.1746199
12. Masiak A, Kulczycka J, Czuszyńska Z, Zdrojewski Z. Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia/Rheumatology. 2016;1:14-18. doi:10.5114/reum.2016.58756
13. Okogbaa J, Batiste L. Dermatomyositis: An Acute Flare and Current Treatments. Clinical Medicine Insights: Case Reports. 2019;12:117954761985537. doi:10.1177/1179547619855370
14. Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin. 2014 Aug;32(3):595-628, vii. doi: 10.1016/j.ncl.2014.04.007. Review. PMID: 25037081
15. Tay MZ, Poh CM1, Rénia L, MacAry PA Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28. doi: 10.1038/s41577-020-0311-8. [Epub ahead of print]

Downloads

Published

2020-07-17

How to Cite

Mantilla, E., Pasnoor, M., & Dimachkie, M. (2020). Rhabdomyolysis and COVID-19 Infection: Is It Due to Statin Use or Anti-TIF1-y Antibodies?. RRNMF Neuromuscular Journal, 1(3), 22–25. https://doi.org/10.17161/rrnmf.v1i3.13719

Issue

Section

Clinic Stuff (Case Reports)